Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Revance rapeutics

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022

A Longer-Acting Botox Competitor is Coming

A Longer-Acting Botox Competitor is Coming

Revance Therapeutics claimed FDA approval for Daxxify. Ramping sales will take years.

Revance Therapeutics's Return On Capital Employed Insights

Revance Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap: Revance Therapeutics Q1 Earnings

Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Revance Therapeutics's Return On Capital Employed Overview

According to Benzinga Pro data, during Q4, Revance Therapeutics (NASDAQ:RVNC) posted sales of $25.95 million. Earnings were up 15.16%, but Revance Therapeutics still reported an overall loss of $63.10 million.

Organisations

Arista Networks

MoffettNathanson

Zoom Video Comms

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play